$EXEL #Cabozantinib #kidneycancer 1st &amp;2nd line = 1.3B peak revenue: current valuation ridiculously low: 950M Revenue FY20 &amp; 1.44B in cash = 7.5B MC 4 phase 3 trials readout 20 $MRK  $bmy $abbv $pfe $azn $sgen $bmrn $agmn $vrtx https://t.co/Wr5eRVhkxV